lead compound

(redirected from Lead compounds)

lead compound

A peptide, small molecule, or other agent with pharmacological or biochemical properties which suggest that it may have therapeutic potential and value as a starting point for drug development.
References in periodicals archive ?
provided a lead compound analysis for obviousness which consisted of two steps: first, determining whether a chemist of ordinary skill in the art would select the prior art compounds as lead compounds for modification and next, determining whether the prior art would provide some motivation or reason to a chemist to modify these lead compounds to make the claimed compound.
The Department of Environment and Natural Resources (DENR) will strengthen its control on the use of lead and its compounds in the local production of consumer products, as well as its importation, sale, distribution and disposal with the issuance of a chemical control order (CCO) for lead and lead compounds.
EPA found that the company failed to report on time for its processing of lead compounds and nitrate compounds in 2010.
number of lead compounds, but is not limited to a single lead compound.
Under the agreement terms, the two companies will strive to identify lead compounds against kinase targets.
Each training and compliance workshop provides these facilities a session focused on the new lead and lead compounds rule, in addition to assistance in understanding and complying with overall EPCRA section 313 regulations.
The new reporting threshold is more than 100 pounds (220 kilograms) annually for a facility emitting lead and lead compounds.
EPA issued the final rule associated with lowering the Toxics Release Inventory (TRI) reporting threshold for lead and lead compounds to 100 Ib/yr.
Suppose, then, he were to add a small quantity of radiolead to lead and use the mixture to produce certain lead compounds.
While lead-based treatments usually are not the first line of defense, he found families often administer several "fingertip"-sized doses of lead compounds daily when other empacho remedies fail.
Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.
Was late in filing inventory reports for dioctylphthalate and lead compounds for calendar years 2007, 2008 and 2009.